Midkine: The Who, What, Where, and When of a Promising Neurotrophic Therapy for Perinatal Brain Injury
| Autor: | David W. Walker, Jenny Kreiner, Emily Ross-Munro, Bobbi Fleiss, Mary Tolcos, Faith A.A. Kwa, Suzanne L. Miller, Madhavi Khore |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Central nervous system Inflammation Review Brain damage neurotrophins midkine Neuroprotection lcsh:RC346-429 neuroinflammation 03 medical and health sciences 0302 clinical medicine medicine lcsh:Neurology. Diseases of the nervous system Neuroinflammation Midkine biology hypoxia business.industry Cell growth preterm birth perinatal brain damage 030104 developmental biology medicine.anatomical_structure Neurology biology.protein Cancer research Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery Neurotrophin |
| Zdroj: | Frontiers in Neurology Frontiers in Neurology, Vol 11 (2020) |
| ISSN: | 1664-2295 |
| DOI: | 10.3389/fneur.2020.568814 |
| Popis: | Midkine (MK) is a small secreted heparin-binding protein highly expressed during embryonic/fetal development which, through interactions with multiple cell surface receptors promotes growth through effects on cell proliferation, migration, and differentiation. MK is upregulated in the adult central nervous system (CNS) after multiple types of experimental injury and has neuroprotective and neuroregenerative properties. The potential for MK as a therapy for developmental brain injury is largely unknown. This review discusses what is known of MK's expression and actions in the developing brain, areas for future research, and the potential for using MK as a therapeutic agent to ameliorate the effects of brain damage caused by insults such as birth-related hypoxia and inflammation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|